Literature DB >> 17391441

Vascular effects of sphingolipids.

Martin C Michel1, Arthur C M Mulders, Maikel Jongsma, Astrid E Alewijnse, Stephan L M Peters.   

Abstract

UNLABELLED: The sphingomyelin metabolites ceramide, sphingosine 1-phosphate (S1P) and sphingosylphosphorylcholine (SPC) are emerging modulators of vascular tone. While ceramide appears to act primarily intracellularly, S1P and SPC appear to mainly work via specific receptors, although those for SPC have not yet been defined unequivocally. Each of the sphingomyelin metabolites can induce both vasoconstriction and vasodilatation and, in some cases--ceramide on the one hand, and S1P and SPC on the other hand--have opposite effects on vascular tone. The differences in effects between vessels may relate to the relative roles of endothelial and smooth muscle cells in mediating them, as well as to the distinct expression patterns of S1P receptors among vascular beds and among endothelial and smooth muscle cells. Recent evidence suggests that vascular tone is not only modulated by sphingomyelin metabolites which are exogenously added or reach the vessel wall via the bloodstream but also by those formed locally by cells in the vessel wall. Such local formation can be induced by known vasoactive agents such as angiotensin II and may serve a signalling function.
CONCLUSION: We conclude that sphingomyelin metabolites are important endogenous modulators of vascular function, which may contribute to the pathophysiology of some diseases and be targets for therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391441     DOI: 10.1111/j.1651-2227.2007.00207.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  14 in total

1.  S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells.

Authors:  Kristen Park Hopson; Jessica Truelove; Jerold Chun; Yumei Wang; Christian Waeber
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  Short-term Mg deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review.

Authors:  Burton M Altura; Nilank C Shah; Gatha J Shah; Aimin Zhang; Wenyan Li; Tao Zheng; Jose Luis Perez-Albela; Bella T Altura
Journal:  Int J Clin Exp Med       Date:  2014-01-15

Review 3.  Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.

Authors:  Mirjam Schuchardt; Markus Tölle; Jasmin Prüfer; Markus van der Giet
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Authors:  Johannes M Aerts; Johanna E Groener; Sijmen Kuiper; Wilma E Donker-Koopman; Anneke Strijland; Roelof Ottenhoff; Cindy van Roomen; Mina Mirzaian; Frits A Wijburg; Gabor E Linthorst; Anouk C Vedder; Saskia M Rombach; Josanne Cox-Brinkman; Pentti Somerharju; Rolf G Boot; Carla E Hollak; Roscoe O Brady; Ben J Poorthuis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

Review 5.  Sphingosine-1-phosphate receptor signalling in the heart.

Authors:  Christopher K Means; Joan Heller Brown
Journal:  Cardiovasc Res       Date:  2009-03-12       Impact factor: 10.787

6.  Protein kinase C-epsilon regulates sphingosine 1-phosphate-mediated migration of human lung endothelial cells through activation of phospholipase D2, protein kinase C-zeta, and Rac1.

Authors:  Irina Gorshkova; Donghong He; Evgeny Berdyshev; Peter Usatuyk; Michael Burns; Satish Kalari; Yutong Zhao; Srikanth Pendyala; Joe G N Garcia; Nigel J Pyne; David N Brindley; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2008-02-22       Impact factor: 5.157

Review 7.  Lipid phosphate phosphatase (LPP3) and vascular development.

Authors:  H Ren; M Panchatcharam; P Mueller; D Escalante-Alcalde; A J Morris; S S Smyth
Journal:  Biochim Biophys Acta       Date:  2012-07-24

8.  Intravenous sphingosylphosphorylcholine protects ischemic and postischemic myocardial tissue in a mouse model of myocardial ischemia/reperfusion injury.

Authors:  Christine Herzog; Martina Schmitz; Bodo Levkau; Ilka Herrgott; Jan Mersmann; Jan Larmann; Kai Johanning; Michael Winterhalter; Jerold Chun; Frank Ulrich Müller; Frank Echtermeyer; Reinhard Hildebrand; Gregor Theilmeier
Journal:  Mediators Inflamm       Date:  2011-01-03       Impact factor: 4.711

9.  The role of sphingosine kinase 1/sphingosine-1-phosphate pathway in the myogenic tone of posterior cerebral arteries.

Authors:  Mihwa Lim; Soo-Kyoung Choi; Young-Eun Cho; Soo-In Yeon; Eok-Cheon Kim; Duck-Sun Ahn; Young-Ho Lee
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

10.  Sphingosylphosphorylcholine potentiates vasoreactivity and voltage-gated Ca2+ entry via NOX1 and reactive oxygen species.

Authors:  Yasin Shaifta; Vladimir A Snetkov; Jesus Prieto-Lloret; Greg A Knock; Sergey V Smirnov; Philip I Aaronson; Jeremy P T Ward
Journal:  Cardiovasc Res       Date:  2015-02-06       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.